Diabetes is a common disease in current society, it can be easily found in middle-aged who have an unhealthy diet. However, only a small portion of them have the condition of T1DM, which is sometimes congenital, and related to genetic factors. One of the common symptoms of T1DM is weight loss. Pramlintide is an analog of the pancreatic β-cell hormone, Amylin. Current studies on Pramlintide focus on exploring Pramlintide’s role in improving glycemic control in T1DM. This article is limited to short-term studies on Pramlintide. This article reviews the mechanisms of T1DM, Amylin and Pramlinte and analyzes two risk factors of T1DM. Additionally, this article analyzes the current study on the role of Pramlintide in the reduction of postprandial glucose, an expected reduction of total daily Insulin dose, and expected weight loss. This paper provides longer study period and multifactorial for Pramlintide studies as a reference for future research. There are side effects problems, such as nausea, that haven’t be solved, so future research can focus on finding adjuvant drug for Pramlintide and Insulin.
